David R Butcher

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Monoclonal Antibody

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Hussein N Al-Ali, Scott J Crichton, Charlene Fabian, Christopher J Pepper, David R Butcher, Fiona C Dempsey, Christopher N Parris
A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo. Oncogene 43 (8) (2024)
Hussein N Al-Ali, Scott J Crichton, Charlene Fabian, Christopher J Pepper, David R Butcher, Fiona C Dempsey, Christopher N Parris
A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo. Oncogene (2024)
Hussein N Al-Ali, Scott J Crichton, Charlene Fabian, Christopher J Pepper, David R Butcher, Fiona C Dempsey, Christopher N Parris
A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo. Oncogene 43 (8) (2024)
Hussein N Al-Ali, Scott J Crichton, Charlene Fabian, Christopher J Pepper, David R Butcher, Fiona C Dempsey, Christopher N Parris
A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo. Oncogene 43 (8) (2024)
Hussein N Al-Ali, Scott J Crichton, Charlene Fabian, Christopher J Pepper, David R Butcher, Fiona C Dempsey, Christopher N Parris
A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo. Oncogene 43 (8) (2024)
Hussein N Al-Ali, Scott J Crichton, Charlene Fabian, Christopher J Pepper, David R Butcher, Fiona C Dempsey, Christopher N Parris
A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo. Oncogene 43 (8) (2024)
Hussein N Al-Ali, Scott J Crichton, Charlene Fabian, Christopher J Pepper, David R Butcher, Fiona C Dempsey, Christopher N Parris
A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo. Oncogene 43 (8) (2024)